G-Zero will use the award to continue studies towards ‘Organismal Radioprotection through Pharmacological Quiescence’.
Previously in late 2009, the company has also received $0.6m through a phase I grant.
G-Zero Therapeutics CSO Jay Strum said this funding will continue to allow G-Zero’s scientists to progress lead candidates through IND-enabling studies.
"We are encouraged by NIAID’s recognition of CDK4/6 inhibitors as radiomitigants, and we are excited to receive this award," Strum said.
G-Zero is focused on the discovery and development of small molecule inhibitors to provide protection of bone marrow and other organs including the kidney and lung from radiation exposure.